Загрузка...
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. In these types of cancer, accurate assessment of HER2 status is mandatory, for selecting patients who may benefit from targeted therapies with anti-HER2 drugs such as Trastuzumab. This manuscript focu...
Сохранить в:
| Опубликовано в: : | World J Gastroenterol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Inc
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4948273/ https://ncbi.nlm.nih.gov/pubmed/27468182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v22.i26.5879 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|